Page 208 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 208
Chapter 7
100 75 50 25
Event free survival Rearrangement [single hit, double or triple hit]
NE single hit 21 7 double or triple hit 53 22
double or triple hit
single hit
Cumulative percentage
00 6 12 At risk:
single hit 21 19 15 double or triple hit 53 44 32 26 Jun 2019
18 months 24
11 7 26 19
Figure S1B
100 75 50 25
Overall survival Rearrangement [single hit, double or triple hit]
ND single hit 21 2 double or triple hit 53 18
double or triple hit
single hit
Cumulative percentage
00 6 12 At risk:
single hit 21 21 20 double or triple hit 53 51 42 26 Jun 2019
18 months 24
15 9 31 21
Figure S1C
Figure S1. Survival according to rearrangement status.
Figure S1A: Disease Free Survival of SH vs DH/TH MYC+ LBCL patients revealed no significant differences. Figure S1B: Event Free Survival of SH vs DH/TH MYC+ LBCL patients revealed no significant differences. Figure S1C: Overall survival analysis indicated that DH/TH patients had a tendency for higher risk of death compared to SH patients (HR 4.18, p=0.055; 95% CI 0.97-18.02). Eight patients with unknown BCL2 and BCL6 rearrangement were not included in this analysis.
206
